Poly(ADP-ribose) Polymerase Inhibitors: all 983 studies that test it
Page 6 of 10. Open to participants first (205), then studies with results posted, then the rest; newest registration first within each.
- Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal AgentsActive, not recruitingNCT06120491Phase 3
- A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital CytomegalovirusCompletedNCT06118515Phase 1
- Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant PembrolizumabWithdrawnNCT06116578Phase 2
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid TumorsActive, not recruitingNCT06077877Phase 1/2
- Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant RecipientsActive, not recruitingNCT06066957Phase 2
- De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant RecipientsCompletedNCT06001320Phase 3
- The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint InhibitorsSuspendedNCT05967533Phase 1
- Preoperative Moderately Fractionated IMRT for Locally Extremity or Trunk Sarcoma (SPARE-03)CompletedNCT05938374Phase 2
- A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.CompletedNCT05938270Phase 1
- Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous CarcinomaActive, not recruitingNCT05870761Phase 2
- Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA MutationsWithdrawnNCT05807126Phase 1
- The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.Status unknownNCT05732129Phase 2
- Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid TumorsCompletedNCT05700669Phase 1/2
- CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene MutationsTerminatedNCT05689021Phase 2
- Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian CancerWithdrawnNCT05672095Phase 1/2
- Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance TherapyStatus unknownNCT05669768Phase 2
- Reirradiation and Niraparib in Patients With Recurrent GlioblastomaWithdrawnNCT05666349Phase 1
- Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes AlterationsActive, not recruitingNCT05659914Phase 2
- Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast CancerSuspendedNCT05656131Phase 2
- Letermovir for Secondary Prophylaxis in Solid Organ Transplant RecipientsCompletedNCT05626530Phase 4
- Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid MalignanciesCompletedNCT05573724Phase 1
- Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment TrialActive, not recruitingNCT05554328Phase 2
- Olaparib in Combination With Pembrolizumab for Advanced Uveal MelanomaActive, not recruitingNCT05524935Phase 2
- A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNAActive, not recruitingNCT05515575Phase 2
- Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene AlterationsActive, not recruitingNCT05498272Phase 2
- Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian CancerCompletedNCT05494580Phase 1/2
- A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor ExposureActive, not recruitingNCT05489926Phase 2
- Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent ChemoradiotherapyStatus unknownNCT05483543Phase 2
- Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2WithdrawnNCT05482074Phase 2
- A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP InhibitorActive, not recruitingNCT05475184Phase 2
- Surgical Pembro +/- Olaparib w TMZ for rGBMActive, not recruitingNCT05463848Phase 2
- Niraparib Efficacy in Patient With Unresectable MesotheliomaCompletedNCT05455424Phase 2
- Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic CancerTerminatedNCT05442749Phase 2
- A Study of Food Effect on the Pharmacokinetics of Fuzuloparib Capsules in Chinese Healthy Adult SubjectsCompletedNCT05440006Phase 1
- Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate CancerSuspendedNCT05425862Phase 1
- Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction TherapyWithdrawnNCT05412706Phase 2
- EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung CancerWithdrawnNCT05411679Phase 2
- Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic CancerActive, not recruitingNCT05411094Phase 1
- Niraparib In Recurrent IDH 1/2 GliomasActive, not recruitingNCT05406700Early Phase 1
- To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate CancerTerminatedNCT05405439Phase 1/2
- An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fed ConditionCompletedNCT05391048Phase 1
- An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fasting ConditionCompletedNCT05390944Phase 1
- A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPiStatus unknownNCT05385068Phase 2
- A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate CancerStatus unknownNCT05376722Phase 2
- Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate CancerActive, not recruitingNCT05367440Phase 1/2
- Pembrolizumab Plus Olaparib in LA-HNSCCActive, not recruitingNCT05366166Phase 2
- Letermovir in ART-treated HIV-infected PersonsCompletedNCT05362916Not applicable
- Combination of Olaparib and Navitoclax in Women with HGSC and TNBCActive, not recruitingNCT05358639Phase 1
- Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.CompletedNCT05340413Phase 2
- A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.Active, not recruitingNCT05335993Phase 2
- Pamiparib in mCRPC With HRD or BRCA1/2 MutationStatus unknownNCT05327621Phase 2
- Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET TrialActive, not recruitingNCT05327010Phase 2
- Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer PatientsCompletedNCT05320757Early Phase 1
- Niraparib Plus Anlotinib for Recurrent Ovarian CancerStatus unknownNCT05311579Phase 2
- Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor TherapyWithdrawnNCT05295589Phase 2
- Niraparib in High-grade Endometrial Cancer TrialWithdrawnNCT05289648Early Phase 1
- Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib As Firstline Therapy in Her-2 Negative Gastric/GEJ AdenocarcinomaCompletedNCT05268510Phase 2
- JS001+IMP4297 in Patients With Advanced CancerWithdrawnNCT05262842Phase 1
- The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene MutationStatus unknownNCT05262608Phase 2
- NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid TumorsTerminatedNCT05252390Phase 1
- Study of INCB123667 in Subjects With Advanced Solid TumorsActive, not recruitingNCT05238922Phase 1
- SMMART Adaptive Clinical Treatment (ACT) TrialWithdrawnNCT05238831Early Phase 1
- Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST TrialActive, not recruitingNCT05223582Phase 2
- Food Effect Study of IDX-1197 in Healthy SubjectsCompletedNCT05202912Phase 1
- Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).Status unknownNCT05201612Phase 2
- A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian CancerCompletedNCT05198804Phase 1/2
- Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC PatientsStatus unknownNCT05174832Phase 2
- Niraparib for the Treatment of LeiomyosarcomaWithdrawnNCT05174455Phase 2
- A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian CancerStatus unknownNCT05170594Phase 2
- The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene MutationStatus unknownNCT05167175Phase 2
- The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung CancerStatus unknownNCT05162196Phase 2
- Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian CancerStatus unknownNCT05158062Phase 2
- A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial CarcinosarcomaCompletedNCT05156268Phase 2
- Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma.CompletedNCT05130515Phase 2
- RBN-2397 in Combination With Pembrolizumab in Patients With SCCLActive, not recruitingNCT05127590Phase 1/2
- Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPiWithdrawnNCT05126342Phase 2
- StrataPATH™ (Precision Indications for Approved Therapies)TerminatedNCT05097599Phase 2
- Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast CancerStatus unknownNCT05085626Phase 2
- Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian CancerCompletedNCT05044871Phase 2
- Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid TumorsCompletedNCT05038839Phase 1
- Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDOActive, not recruitingNCT05033756Phase 2
- Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Kidney FunctionCompletedNCT05032235Phase 1
- A Clinical Study of TQB3823 in Patients With Advanced Malignant TumorActive, not recruitingNCT05021367Phase 1
- XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate CancerCompletedNCT05005728Phase 2
- Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid TumorsCompletedNCT05002868Phase 1
- Niraparib in Tumors Metastatic to the CNSActive, not recruitingNCT04992013Phase 2
- UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLCStatus unknownNCT04940637Phase 2
- A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsActive, not recruitingNCT04931342Phase 2
- A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal CancersTerminatedNCT04926324Phase 1
- Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent GlioblastomaActive, not recruitingNCT04910022Phase 1/2
- Maintenance Niraparib and Dostarlimab in Advanced CholangiocarcinomaWithdrawnNCT04895046Phase 2
- D9319C00001- 1L OC Mono Global RCTActive, not recruitingNCT04884360Phase 3
- A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate CancerCompletedNCT04869488Phase 2
- Phase Ia/Ib Talazoparib + Tazemetostat for mCRPCActive, not recruitingNCT04846478Phase 1
- Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast CancerActive, not recruitingNCT04837209Phase 2
- Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung CancerStatus unknownNCT04828395Phase 2
- Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 MonthsTerminatedNCT04826198Phase 1/2
- Telaglenastat + Talazoparib In Prostate CancerWithdrawnNCT04824937Phase 2
- Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPCActive, not recruitingNCT04821622Phase 3
- Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot StudyTerminatedNCT04801966Not applicable